Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)

Summary

Background :

Based on several clinical trials, eucalyptus oil can suppress edema formation and reduce inflammation, where the effect of 1,8-cineole is due to the inhibition of cytokine secretion by T lymphocytes. This but not limited to the reduction of interleukin (IL) of IL-4, IL-5, and IL-10 in nasal lavage fluids and levels of IL- 1β, IL-6, Tumor Necrosis Factor-α (TNF-α), and Interferon-γ (IFN-γ) in lung tissue of mice infected with influenza virus. Hence the researchers assume that Eucalyptus may possess benefits in COVID-19 as adjuvant therapy.

Objectives :

The primary objective of this study is to evaluate the efficacy of Eucalyptus oil as adjuvant therapy in mild-moderate COVID-19 patients.

Hypothesis :

Eucalyptus oil may reduce the inflammatory cytokines which eventually improves clinical symptoms

Conditions

• COVID-19

Interventions

DRUG

Eucalyptus Oil

The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.

DRUG

Standard COVID medication

This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.

Sponsors & Collaborators

• Ministry of Agriculture, Republic of Indonesia

  collaborator UNKNOWN

• Hasanuddin University

  lead OTHER

Principal Investigators

• Arif Santoso, MD, Ph.D · Hasanuddin University

• Idrus Paturusi, Prof. · Hasanuddin University

• Nasrum Massi, Prof. · Hasanuddin University

• Idrianti Idrus, MD · Hasanuddin University

• Firdaus Hamid, MD. PhD · Hasanuddin University

• Andi Rofian Sultan, MD. Ph.D · Hasanuddin University

• Munawir Munawir, MD · Hasanuddin University

• Rasiha Rasiha · Hasanuddin University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

59 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-18

Primary Completion

2021-01-28

Completion

2022-03-01

Countries

• Indonesia

Study Locations